Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal

Covers Novel Cancer Immunotherapy Targets And Therapies

Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.

Cancer cell and T cells
'Dark antigens' are hidden targets for immunotherapies which could be revealed thanks to new drug discovery techniques

Boehringer Ingelheim has signed a deal with Enara Bio to explore the potential of what the UK biotech calls ‘dark antigens’ – antigens derived from the genomic ‘dark matter’ or the 98% of the genome that is not normally expressed, but which could yield many new targets for cancer immunotherapies.

The collaboration will focus on the discovery and validation of up to three dark antigens for lung and gastrointestinal cancers,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip